Sanofi shares boosted by Q1 beat helped by Dupixent sales

Sanofi SA

23/04/2026 09:14

** Sanofi SASY.PA shares rise around about 3% after the drugmaker posted a quarterly earnings beat, driven by its blockbuster eczema and asthma drug, Dupixent

** The French group posts sales of EUR 10.51 billion ($12.29 billion), 3% over consensus, with business EPS at EUR 1.88 beating consensus by 6%

** Dupixent sales also outperform expectations by 6%

** "We expect the strong set of results (...) should be well received today," analysts at J.P. Morgan say

** Jefferies notes the higher sales combined with lighter R&D costs "more than offsets" a softer gross margin

** Sanofi reiterates its 2026 outlook

($1 = 0.8548 euros)

(Reporting by Jakob Van Calster)

((jakob.vancalster@thomsonreuters.com))